Thymus alpha-sin for injection

[Pharmacological Action] The mechanism of action of this product in treating chronic hepatitis B and enhancing the responsiveness of the immune system has not been fully elucidated. Several in vitro tests have shown that this product promotes the maturation of T lymphocytes by stimulating peripheral blood lymphocyte mitogens, increases the levels of lymphokines such as interferon α, interferon γ, interleukin 2, and interleukin 3 secreted by T cells after antigen or mitogen activation, and increases the level of lymphokine receptors on the surface of T cells. This product can also enhance allogeneic and autologous human mixed lymphocyte reactions by activating CD4 cells. This product may increase the aggregation of pre-NK cells, and interferon can enhance their cytotoxicity. In vivo tests have shown that this product can increase the expression level of interleukin 2 receptors in mouse lymphocytes after activation by concanavalin A, and at the same time increase the secretion level of interleukin 2. Toxicological studies Genetic toxicity: The results of the genetic toxicity test of this product are negative. Reproductive toxicity: This product has no obvious teratogenic effect on animal fetuses. It is not clear whether the use of this product by pregnant women will affect their reproductive ability or cause damage to the fetus. Pregnant women can only use this product when it is really necessary. Similarly, it is not clear whether this product can be secreted through human milk, so lactating women should be cautious when using this product.

Each bottle contains 11.6 mg of thymosin α and 14.4 mg of mannitol.

This product is a white loose mass.

1. Chronic hepatitis B. 2. As a vaccine immune response enhancer for immunocompromised patients. For patients with suppressed immune system function, including those receiving chronic hemodialysis and elderly patients, this product can enhance the patient's immune response to viral vaccines, such as influenza vaccine or hepatitis B vaccine.

Before use, dissolve each bottle of thymosin α1 (1.6mg) in 1ml of water for injection and inject subcutaneously immediately (do not inject intramuscularly or intravenously). Recommended dose for the treatment of chronic hepatitis B: 1.6mg each time, twice a week, 3-4 days apart. Continuous administration for 6 months (52 injections in total) without interruption.

Thymosin α1 is well tolerated. Some patients may experience discomfort at the injection site. When patients with chronic hepatitis B receive this product, ALT levels may temporarily fluctuate to more than twice the baseline value. At this time, it should usually be continued unless symptoms and signs of liver failure appear.

It is contraindicated for patients who are allergic to the ingredients of this product; it is contraindicated for patients who are receiving immunosuppressive therapy such as organ transplant recipients.

Precautions for children: The safety and effectiveness of this product for patients under 18 years old have not been determined. Precautions for pregnancy and lactation: Basic research shows that this product has no effect on animal embryos, but whether it will have an effect on pregnant embryos clinically and whether this product is excreted through breast milk is still unclear, so some patients should use the drug with caution.

This product can be used in combination with alpha interferon to enhance immune response, but should be used with caution in combination with other drugs. This product should not be mixed with any other drugs for injection.

Sealed, protected from light, stored at 2-8℃.

1.6mg

30 months

Chengdu DIAO Jiuhong Pharmaceutical Factory

• Founded in:

  1996-11-27

• Address:

  No. 16, Gaopeng East Road, Chengdu Hi-tech Zone

• Tax NO.:

  91510100202172097P

• Registered Funds:

  10 million yuan

• Website:

  Log in to view

• Email:

  Log in to view